€43M Series C to Launch UK Company’s Home Hemodialysis Kit

Quanta Dialysis Technologies has raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients.

The UK-based Quanta will use the money to launch its technology in the UK later this year, and also apply for FDA approval. The technology previously obtained a CE mark in 2015, clearing it for commercial launch in the EU.

Normally, people with kidney failure need long appointments in hospitals for hemodialysis. While it is possible to carry out the procedure more flexibly in the patient’s house, the equipment is bulky, expensive, and hard for the patient to use independently. Quanta aims to solve this problem with its lightweight equipment with disposable cartridges, making it easier for a patient to use at home.

ADVERTISEMENT

There are approximately 3.5 million dialysis patients globally and there has been very little innovation over the years,” stated Christian Schütz, Partner at one of the round’s lead investors, the German VC firm btov Partners. The other investors leading the round were Germany-based Wellington Partners and Irish VC firm Seroba Life Sciences.

Quantas’ technology has shown promise for making home hemodialysis easier in pilot studies in the UK and France. In Quanta’s latest pilot study, a group of 32 healthcare professionals and home users were trained with the device for up to six hours, and tested to see how safe and easy the device was. Out of 1216 tasks the group carried out with the device, there were just 29 minor errors, and none had an impact on the safety of the device.

As well as allowing home testing, the device is also designed to be usable in hospitals as a more portable alternative to traditional machines.

Another company aiming to improve the hemodialysis process is the Estonian biotech Optofluid Technologies, which is developing sensors that give real-time feedback on the process’s effectiveness.


Images from Shutterstock

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.